Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Immunoblastic Lymphadenopathy 1

Interventions

pegaspargase 14Etoposide 11Dexamethasone 11Gemcitabine 10spartalizumab 6Oxaliplatin 4sintilimab 3Radiotherapy 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methotrexate 3Asparaginase 3tislelizumab 2camrelizumab 2Lenalidomide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2Busulfan 2Azacitidine 2toripalimab 1tofacitinib 1ruxolitinib 1romidepsin 1pembrolizumab 1fludarabine phosphate 1avelumab 1apatinib 1Thalidomide 1Sensitivity and Specificity 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Extranodal NK-T-Cell × romidepsin × Clear all
NCT02232516 2024-04-10

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Northwestern University

Phase 2 Unknown
30 enrolled 17 charts
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡